- Home
- NXG vs PLX Comparison
NXG vs PLX Comparison
Compare NXG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXG
- PLX
- Stock Information
- Founded
- NXG 2012
- PLX 1993
- Country
- NXG United States
- PLX Israel
- Employees
- NXG N/A
- PLX N/A
- Industry
- NXG
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXG
- PLX Health Care
- Exchange
- NXG Nasdaq
- PLX Nasdaq
- Market Cap
- NXG 124.2M
- PLX 132.5M
- IPO Year
- NXG N/A
- PLX 1998
- Fundamental
- Price
- NXG $42.01
- PLX $1.74
- Analyst Decision
- NXG
- PLX
- Analyst Count
- NXG 0
- PLX 0
- Target Price
- NXG N/A
- PLX N/A
- AVG Volume (30 Days)
- NXG 24.4K
- PLX 404.5K
- Earning Date
- NXG 01-01-0001
- PLX 11-14-2024
- Dividend Yield
- NXG 14.78%
- PLX N/A
- EPS Growth
- NXG N/A
- PLX N/A
- EPS
- NXG N/A
- PLX N/A
- Revenue
- NXG N/A
- PLX $45,667,000.00
- Revenue This Year
- NXG N/A
- PLX N/A
- Revenue Next Year
- NXG N/A
- PLX $88.94
- P/E Ratio
- NXG N/A
- PLX N/A
- Revenue Growth
- NXG N/A
- PLX N/A
- 52 Week Low
- NXG $30.32
- PLX $0.82
- 52 Week High
- NXG $42.29
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- NXG 32.29
- PLX 63.08
- Support Level
- NXG $45.70
- PLX $1.57
- Resistance Level
- NXG $47.58
- PLX $1.83
- Average True Range (ATR)
- NXG 1.87
- PLX 0.07
- MACD
- NXG -0.97
- PLX -0.01
- Stochastic Oscillator
- NXG 1.50
- PLX 65.38
About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest
Cushing NextGen Infrastructure Income Fund is a closed-end investment management company. Its investment objective is to seek a high total return with a focus on current income. The Fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies, and technology & communication infrastructure companies.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.